deferitazole

Deferitazole is an investigational small molecule iron chelator of the desazadesferrithiocin class, developed originally by FerroKin BioSciences (later acquired by Shire, and then Takeda). It binds Fe(III) with high affinity and selectivity over Fe(II) and other biologically important metals. Deferitazole was studied for the treatment of iron overload conditions such as beta-thalassemia and transfusional iron overload. Clinical development reached phase 2 trials but was discontinued due to safety concerns, including a high incidence of peripheral neuropathy at higher doses and findings of malignant kidney tumors in preclinical rat studies. The FDA placed a full clinical hold on further trials in 2014[1][2][4][8].

Other names

deferitazole(S)3”-(HO)-desazadesferrithiocin-polyetherDADFT-PE